| | Important Notice Regarding the Availability of Proxy Materials for the to Be Held on via live webcast at https://web.lumiagm.com/ | | |
| | The proxy statement and at https://www.astproxyportal.com/ast/ | | |
| | Your vote is very important to us. Whether or not you expect to attend the | | |
| | | Page | | ||||
| | | | 1 | | | ||
| | | | | | |||
| | | | 6 | | | ||
| | | | 11 | | | ||
| | | | | | |||
| | | | 12 | | | ||
| | | | 12 | | | ||
| | | | 12 | | | ||
| | | | 13 | | | ||
| | | | 13 | | | ||
| | | | 13 | | | ||
| | | | 14 | | | ||
| | | | 15 | | | ||
| | | | 16 | | | ||
| | | | 16 | | | ||
| | | | 16 | | | ||
| | | | | | |||
| | | | 18 | | | ||
| | | | 19 | | | ||
| | | | 20 | | | ||
| | | | 21 | | | ||
| | | | 23 | | | ||
| | | | 24 | | | ||
| | | | 24 | | | ||
| | | | 25 | | | ||
| | | | 26 | | | ||
| | | | 28 | | | ||
| | | | 28 | | | ||
| | | | 29 | | | ||
| | | | 32 | | | ||
| | | | | | |||
| | | | |||||
| |
| | Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your | | |
Proposal Number | | | Proposal Description | | | Vote Required for Approval | | | Effect of Abstentions | | | Effect of Broker Non-Votes | |
1 | | | Election of Class III Directors | | | Nominees receiving the most “For” votes | | | Withheld votes will have no effect | | | None | |
2 | | | Ratification of KPMG LLP as Independent Registered Public Accounting Firm for fiscal year 2022 | | | “For” votes from the holders of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote on the subject matter | | | Against | | | N/A | |
3 | | | A non-binding advisory vote on the compensation of Outlook Therapeutics Inc.’s named executive officers | | | “For” votes from the holders of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote on the subject matter | | | Against | | | None | |
4 | | | A non-binding advisory vote on the frequency of future advisory votes on the compensation of Outlook Therapeutics Inc.’s named executive officers | | | The option receiving the most votes for either “One Year,” “Two Years,” or “Three Years” | | | Withheld votes will have no effect | | | None | |
NAME | | | AGE(1) | | | PRINCIPAL OCCUPATION/POSITION HELD WITH THE COMPANY | |
Ralph H. “Randy” Thurman | | | 72 | | | Executive Chairman, Class III | |
C. Russell Trenary III | | | 64 | | | President, Chief Executive Officer and Director, Class III | |
Julian Gangolli | | | 64 | | | Director, Class III | |
| | | As of July 31, 2020 | | |||
Total shares subject to outstanding stock options | | | | | 3,819,726 | | |
Weighted-average exercise price per share of outstanding stock options | | | | $ | 2.01 | | |
Weighted-average remaining term of outstanding stock options | | | | | 9.5 | | |
Total number of shares of common stock subject to outstanding full value awards | | | | | 2,470 | | |
Total shares available for grant under the 2015 Plan | | | | | 33,148 | | |
Total shares available for grant under other equity plans(1) | | | | | 68,145 | | |
| | | As of August 6, 2020 (Record Date) | | |||
Total common stock outstanding | | | | | 127,183,109 | | |
Closing price of common stock as reported on the Nasdaq Capital Market | | | | $ | 1.28 | | |
Key Equity Metrics | | | 2017 | | | 2018 | | | 2019 | | |||||||||
Burn Rate(1) | | | | | 2.56% | | | | | | 4.28% | | | | | | 7.97% | | |
Overhang(2) | | | | | 9.70% | | | | | | 18.26% | | | | | | 14.93% | | |
Dilution(3) | | | | | 4.47% | | | | | | 2.28% | | | | | | 4.91% | | |
NAME | | | AGE(1) | | | PRINCIPAL OCCUPATION/ POSITION HELD WITH THE COMPANY, CLASS | |
Lawrence A. Kenyon | | | 56 | | | Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director, Class II | |
Gerd Auffarth | | | 57 | | | Director, Class II | |
Yezan Haddadin | | | 46 | | | Director, Class I | |
Kurt J. Hilzinger | | | 61 | | | Director, Class I | |
Faisal G. Sukhtian | | | 37 | | | Director, Class I | |
Andong Huang | | | 25 | | | Director, Class II | |
Name | | | Audit | | | Compensation | | | Nominating and Corporate Governance | | | Executive | |
C. Russell Trenary III | | | | | | | | | | | | X | |
Lawrence A. Kenyon | | | | | | | | | | | | X | |
Kurt J. Hilzinger | | | X* | | | X | | | | | | | |
Faisal G. Sukhtian | | | | | | | | | X* | | | X | |
Ralph “Randy” H. Thurman | | | | | | X* | | | X | | | X | |
Yezan Haddadin | | | X | | | X | | | | | | X | |
Julian Gangolli | | | X | | | | | | | | | X | |
Gerd Auffarth | | | | | | | | | X | | | | |
Andong Huang | | | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, | | |||||||||
| | | 2021 | | | 2020 | | ||||||
Audit Fees | | | | $ | 522,000 | | | | | $ | 318,000 | | |
Tax Fees | | | | | 107,980 | | | | | | 31,403 | | |
Total Fees | | | | $ | 629,980 | | | | | $ | 349,403 | | |
Plan Category | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights | | | Weighted- average exercise price of outstanding options, warrants and rights ($) | | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (#) | | |||||||||
| | | (a) | | | (b) | | | (c) | | |||||||||
Equity compensation plans approved by security holders: | | | | | | | | | | | | | | | | | | | |
2011 Stock Incentive Plan | | | | | 15,691 | | | | | $ | 49.97(1) | | | | | | —(2) | | |
2015 Equity Incentive Plan | | | | | 1,390,108(3) | | | | | $ | 3.46(3) | | | | | | 1,309,950(4) | | |
2016 Employee Stock Purchase Plan | | | | | — | | | | | | — | | | | | | 68,145(5) | | |
Equity compensation plans not approved by security holders: | | | | | | | | | | | | | | | | | | | |
None | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 1,405,799 | | | | | | | | | | | | 1,378,095 | | |
| | | Common Stock | | |||||||||
Name of Beneficial Owner | | | Number of Shares Beneficially Owned | | | % | | ||||||
Five Percent Stockholders (other than directors and officers): | | | | | | | | | | | | | |
BioLexis Pte. Ltd.(1) | | | | | 50,965,058 | | | | | | 22.7% | | |
Syntone Ventures, LLC(2) | | | | | 19,823,045 | | | | | | 8.8% | | |
GMS Ventures and Investments(3) | | | | | 29,064,572 | | | | | | 12.9% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
C. Russell Trenary III, Director, President and Chief Executive Officer | | | | | 35,000 | | | | | | * | | |
Lawrence A. Kenyon, Director, Chief Financial Officer, Treasurer and Corporate Secretary(4) | | | | | 1,503,764 | | | | | | * | | |
Jeff Evanson, Chief Commercial Officer | | | | | 1,177,130 | | | | | | * | | |
Terry Dagnon, Chief Operations Officer | | | | | 1,163,058 | | | | | | * | | |
Ralph H. “Randy” Thurman, Executive Chairman(5) | | | | | 1,168,885 | | | | | | * | | |
Gerd Auffarth, M.D, Director(6) | | | | | 265,977 | | | | | | * | | |
Julian Gangolli, Director(7) | | | | | 351,076 | | | | | | * | | |
Yezan Haddadin, Director(8) | | | | | 764,708 | | | | | | * | | |
Kurt J. Hilzinger, Director(9) | | | | | 717,020 | | | | | | * | | |
Andong Huang, Director(10) | | | | | 249,124 | | | | | | * | | |
Faisal G. Sukhtian, Director(11) | | | | | 769,906 | | | | | | * | | |
All executive officers and directors as a group (11 persons) | | | | | 8,165,648 | | | | | | 3.6% | | |
Name | | | Age | | | Position(s) | |
C. Russell Trenary III | | | 64 | | | Director, President and Chief Executive Officer | |
Lawrence A. Kenyon | | | 56 | | | Director, Chief Financial Officer, Treasurer and Corporate Secretary | |
Terry Dagnon | | | 60 | | | Chief Operations Officer | |
Jeff Evanson | | | 53 | | | Chief Commercial Officer | |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($)(1) | | | Option Awards ($)(2) | | | All Other Compensation ($)(3) | | | Total ($) | | ||||||||||||||||||
C. Russell Trenary III(4) | | | | | 2021 | | | | | $ | 145,384 | | | | | $ | — | | | | | $ | 7,304,000 | | | | | $ | 6,228 | | | | | $ | 7,455,612 | | |
President and Chief Executive Officer | | | | | 2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Lawrence A. Kenyon(4) | | | | | 2021 | | | | | | 425,000 | | | | | | 212,500 | | | | | | 2,008,035 | | | | | | 23,679 | | | | | | 2,669,214 | | |
Executive Vice President, | | | | | 2020 | | | | | | 425,000 | | | | | | 116,875 | | | | | | 621,449 | | | | | | 21,010 | | | | | | 1,184,334 | | |
Chief Financial Officer, | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Treasurer and Corporate Secretary | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Terry Dagnon(5) | | | | | 2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | 300,000 | | | | | | 300,000 | | |
Chief Operations Officer | | | | | 2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | 159,677 | | | | | | 159,677 | | |
Jeff Evanson(5) | | | | | 2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | 300,000 | | | | | | 300,000 | | |
Chief Commercial Officer | | | | | 2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | 159,677 | | | | | | 159,677 | | |
| | | Option awards(1) | | |||||||||||||||||||||||||||
| | | Grant date | | | Number of securities underlying unexercised options (#) exercisable | | | Number of securities underlying unexercised options (#) unexercisable | | | Equity incentive plan awards: Number of securities underlying unexercised unearned options (#) | | | Option exercise price ($) | | | Option expiration date | | ||||||||||||
C. Russell Trenary III | | | 07/06/2021 | | | | | — | | | | | | 4,000,000(2) | | | | | | — | | | | | | 2.42 | | | | 07/06/2030 | |
| | | 07/06/2021 | | | | | — | | | | | | — | | | | | | 500,000(4) | | | | | | 2.42 | | | | 07/06/2030 | |
| | | 07/06/2021 | | | | | — | | | | | | — | | | | | | 500,000(4) | | | | | | 2.42 | | | | 07/06/2030 | |
Lawrence A. Kenyon | | | 08/01/2018 | | | | | 46,875 | | | | | | 15,625(3) | | | | | | — | | | | | | 6.88 | | | | 08/01/2028 | |
| | | 02/19/2019 | | | | | 50,000 | | | | | | 50,000(3) | | | | | | — | | | | | | 10.56 | | | | 02/19/2029 | |
| | | 09/12/2019 | | | | | 225,000 | | | | | | 225,000(3) | | | | | | — | | | | | | 1.75 | | | | 09/12/2029 | |
| | | 03/19/2020 | | | | | 54,108 | | | | | | 162,327(3) | | | | | | — | | | | | | 0.54 | | | | 03/19/2030 | |
| | | 07/17/2020 | | | | | 112,500 | | | | | | 337,500(3) | | | | | | — | | | | | | 1.58 | | | | 07/17/2030 | |
| | | 10/01/2020 | | | | | 46,875 | | | | | | 3,668,984(3) | | | | | | — | | | | | | 0.71 | | | | 10/01/2030 | |
Name | | | Fees Earned or Paid in Cash(1) ($) | | | Option Awards(2)(3) ($) | | | Total ($) | | |||||||||
Randy Thurman | | | | | — | | | | | | 374,379 | | | | | | 374,379 | | |
Gerd Auffarth | | | | | — | | | | | | 79,000 | | | | | | 79,000 | | |
Julian Gangolli | | | | | — | | | | | | 112,500 | | | | | | 112,500 | | |
Kurt Hilzinger | | | | | — | | | | | | 208,610 | | | | | | 208,610 | | |
Yezan Haddadin | | | | | — | | | | | | 269,103 | | | | | | 269,103 | | |
Andong Huang | | | | | — | | | | | | 75,000 | | | | | | 75,000 | | |
Faisal G. Sukhtian | | | | | — | | | | | | 267,725 | | | | | | 267,725 | | |
Board Committee | | | Chairperson Fee | | | Member Fee | | ||||||
Audit Committee | | | | $ | 15,000 | | | | | $ | 7,500 | | |
Compensation Committee | | | | | 10,000 | | | | | | 5,000 | | |
Nominating and Corporate Governance Committee | | | | | 8,000 | | | | | | 4,000 | | |
Executive Committee | | | | | — | | | | | | 30,000 | | |
| | | Option awards | | |||||||||||||||||||||||||||
Name | | | Grant date | | | Number of options granted | | | Grant date fair value ($) | | | Option exercise price ($) | | | Option expiration date | | |||||||||||||||
Randy Thurman | | | | | 10/1/2020 | | | | | | 259,297 | | | | | | 0.5221 | | | | | | 0.71 | | | | | | 10/1/2030 | | |
Kurt J. Hilzinger | | | | | 10/1/2020 | | | | | | 217,602 | | | | | | 0.5221 | | | | | | 0.71 | | | | | | 10/1/2030 | | |
Yezan Haddadin | | | | | 10/1/2020 | | | | | | 290,372 | | | | | | 0.5221 | | | | | | 0.71 | | | | | | 10/1/2030 | | |
| | | Option awards | | |||||||||||||||||||||||||||
Name | | | Grant date | | | Number of options granted | | | Grant date fair value ($) | | | Option exercise price ($) | | | Option expiration date | | |||||||||||||||
Faisal Sukhtian | | | | | 10/1/2020 | | | | | | 296,353 | | | | | | 0.5221 | | | | | | 0.71 | | | | | | 10/1/2030 | | |
Randy Thurman | | | | | 10/5/2020 | | | | | | 396,809 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Kurt Hilzinger | | | | | 10/5/2020 | | | | | | 116,708 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Yezan Haddadin | | | | | 10/5/2020 | | | | | | 160,474 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Faisal Sukhtian | | | | | 10/5/2020 | | | | | | 151,721 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Julian Gangolli | | | | | 10/5/2020 | | | | | | 150,748 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Gerd Auffarth | | | | | 10/5/2020 | | | | | | 85,586 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Andong Huang | | | | | 10/5/2020 | | | | | | 77,805 | | | | | | 0.5141 | | | | | | 0.7052 | | | | | | 10/5/2030 | | |
Gerd Auffarth | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | 3/24/2031 | | |
Yezan Haddadin | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | .3/24/2031 | | |
Kurt Hilzinger | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | .3/24/2031 | | |
Andong Huang | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | .3/24/2031 | | |
Randy Thurman | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | .3/24/2031 | | |
Julian Gangolli | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | .3/24/2031 | | |
Faisal Sukhtian | | | | | 3/24/2021 | | | | | | 20,873 | | | | | | 1.6768 | | | | | | 2.27 | | | | | | .3/24/2031 | | |